House Passes Marrow and Cord-Blood Reauthorization; Senate Work Remains

For patients who need an unrelated blood stem-cell transplant, the search for a donor depends on a national system built to connect transplant centers, volunteer donors, cord-blood banks and patient-support services. On July 20, the U.S. House of Representatives voted to continue the federal authorization behind that system, passing H.R. 5160 as amended under suspension of the rules.

The vote was consequential, but it was not the final vote Congress must take. The House acted on one bill; the Senate has a related measure that has advanced through committee but, as of July 26, remained at the reported-bill stage. The chambers also have not yet approved identical legislative text, a requirement before a measure can be sent to the president.

That procedural accuracy matters. Calling the House vote a completed reauthorization would move the story ahead of the law. Calling the legislation a $280 million appropriation would confuse permission to fund a program with the separate act of supplying the money. What happened in the House is best understood as a substantial bipartisan step—and as a prompt for close attention to what comes next.

What the House passed

The House measure’s official short title is the Stem Cell Therapeutic and Research Reauthorization Act of 2025. That date belongs to the House bill even though Congress is considering it in 2026; the Senate’s related bill carries a different short title and date.

Representative Chris Smith of New Jersey introduced H.R. 5160 with Representatives Doris Matsui, Gus Bilirakis, Chellie Pingree, Claudia Tenney and Kweisi Mfume as original cosponsors. On May 21, the House Energy and Commerce Committee ordered the bill favorably reported by a recorded vote of 46–0.

That 46–0 tally was a committee vote, not the later vote of the full House. The July 20 Congressional Record says that two-thirds were in the affirmative and that the amended bill passed under suspension of the rules, but it does not publish a numbered floor tally. The public record therefore supports saying that the House passed the bill; it does not support describing the full House vote as “46–0” or assigning it an unrecorded numerical count.

The bill would reauthorize two connected federal efforts through fiscal year 2031. It would authorize up to $33.009 million in each fiscal year from 2027 through 2031 for the C.W. Bill Young Cell Transplantation Program. It would also extend an authorization of up to $23 million annually over the same five fiscal years for the National Cord Blood Inventory.

The annual figures in the House report total approximately $280 million over five years: $165.045 million for the transplantation program and $115 million for the cord-blood inventory. The House debate itself described the combined authorization as approximately $280 million over five years.

Authorization is not appropriation

The word authorize is doing essential work. H.R. 5160 would extend the statutory authorizations of appropriations through fiscal year 2031 and specify the amounts Congress is authorizing for those years. It would not itself provide budget authority.

The House committee’s required budget-authority statement says the bill would result in no new or increased budget authority; the report also notes that a Congressional Budget Office cost estimate was not available when the report was filed. Actual spending would still depend on future appropriations. In practical terms, reauthorization extends the programs’ statutory funding authorizations; appropriations provide money through a separate congressional process.

The House bill also reaches beyond a five-year extension. Its cord-blood provisions would move away from a fixed inventory target and direct the Department of Health and Human Services to determine a sufficient supply using scientific and clinical standards. The reported text also addresses the transfer of units from banks that are no longer operational or no longer meet specified requirements and calls for inventory management that advances clinical utility, genetic diversity and efficient use of resources.

The infrastructure behind a match

The federal program is more than a roster of potential donors. The Health Resources and Services Administration describes a structure organized through three major contracts: a single point of access and coordinating center, an outcomes database, and an office of patient advocacy. Together, those functions support donor and cord-blood recruitment, a searchable system, product distribution, transplant-outcome information and help for patients navigating the process, according to HRSA’s official description of the program’s contracts.

The program also has a history longer than its current name. The federal registry effort began in 1987, the Department of Health and Human Services received formal responsibility in 1990, and HRSA assumed oversight in 1994. Congress established the C.W. Bill Young Cell Transplantation Program in 2005 as the successor to the National Bone Marrow Donor Registry and reauthorized the work in 2010, 2015 and 2021, according to HRSA’s legislative history.

NMDP participates in this system as a federal contractor; it is not the entire federal program. At a June event held with HRSA, NMDP described the work as a coordinated effort involving NMDP, the Medical College of Wisconsin and public cord-blood banks, with HRSA providing federal oversight. That account is set out in NMDP’s report on the joint HRSA event, while HRSA’s own contracts page defines the functions assigned across the program.

That distinction does not diminish NMDP’s role. It clarifies it. NMDP operates the nation’s donor registry under contract, recruits potential donors and helps facilitate matches, while the federal program encompasses additional coordinating, outcomes, cord-blood and patient-support responsibilities described by HRSA.

A separate Senate track

The Senate is considering S. 4109, whose official short title is the Stem Cell Therapeutic and Research Reauthorization Act of 2026. The difference between “2025” in the House title and “2026” in the Senate title is not a typo; it reflects two separately introduced measures.

Senator Jack Reed of Rhode Island introduced S. 4109 on March 17 with Senators Tim Scott, Tina Smith and James Lankford as original cosponsors, according to the official Senate text and legislative history. On June 17, the Senate Health, Education, Labor and Pensions Committee agreed to a manager’s amendment by voice vote and then approved the amended bill by a 22–0 committee roll call.

As with the House committee’s 46–0 vote, the Senate committee’s 22–0 tally must not be mistaken for passage by the full chamber. S. 4109 was reported to the Senate on June 22 and placed on the legislative calendar as Calendar No. 443. The House-passed H.R. 5160 also reached the Senate calendar on July 21 as Calendar No. 464, cross-referenced to S. 4109. Neither measure had passed the full Senate as of July 26.

The Senate-reported measure is closely related to the House bill, but the texts are not identical. The Senate version would update the existing biennial state-of-the-science review by restarting its schedule, expanding its scope to high-quality cord-blood units and other emerging technologies, and resetting the deadline for recommendations to Congress. It also would direct the secretary to consult the Advisory Council on Blood Stem Cell Transplantation, as appropriate, when managing the cord-blood inventory. Those provisions appear in the reported Senate text and not in the House-reported text.

The next steps are therefore concrete. The Senate must act on the legislation. If it approves language different from the House version, the chambers must resolve those differences and pass the same text. The resulting enrolled bill could then be presented to the president; the constitutional sequence is described in the House’s official legislative-process guide and the House’s guide to resolving differences between House and Senate bills. Even if reauthorization becomes law, future appropriations would remain necessary to provide the authorized funds.

Jeana Moore and the work before the match

The legislative story concerns infrastructure. Jeana Moore’s story concerns the human work that helps people enter it.

According to the Jada Bascom Foundation’s public history of Moore’s work, her granddaughter Jada received a transplant from an international donor, Torsten Huber of Germany, who had registered through DKMS. A contemporaneous DKMS account identified Huber as Jada’s donor and documented the family’s 2011 meeting. The Spokesman-Review later reported that Moore founded the Jada Bascom Foundation and built Steps to Marrow around public education, walking campaigns and donor-registration outreach.

This article does not attribute H.R. 5160 advocacy to Moore. Her documented public work is the sustained, public-facing effort to explain why donor registration matters and direct willing volunteers toward the official systems that can register and match them. The Foundation’s registry guidance sends people in the United States to NMDP and directs people in other countries to their national registry. The Foundation does not operate a marrow registry itself.

That work supplies a necessary civic counterpart to the legislation. Congress can authorize a national program, HRSA can oversee it, and contractors can maintain the systems that make searches possible. But a potential donor still has to learn that the registry exists and decide to join. Steps to Marrow is built around that decision, one community and one person at a time.

Eligible U.S. residents ages 18 to 35 can learn the requirements and join through NMDP’s official donor-registry page. Readers outside the United States can use the Foundation’s country-by-country registry finder to locate the appropriate organization.

The work still ahead

The House vote gives the reauthorization effort momentum and follows a public record of broad committee support. It does not conclude the legislative process, guarantee an appropriation or erase the differences between the House and Senate texts. As of July 26, Senate action, agreement on identical language and presidential consideration, and later funding decisions still stood between the House vote and a fully funded next chapter for the programs.

For patients and families, those procedural distinctions are not abstractions. They shape the legal and fiscal conditions for the institutions behind donor searches, cord-blood access, patient navigation and transplant-outcome tracking—and whether Congress later provides the resources those institutions are authorized to receive.

Sources

• H.R. 5160 House report, H. Rept. 119-724
• Congressional Record, July 20, 2026
• S. 4109, reported Senate text
• Senate Calendar of Business recording H.R. 5160 as Calendar No. 464
• Senate HELP Committee markup record, June 17, 2026
• HRSA program contracts and legislative history
• Jeana Moore and Steps to Marrow
• Independent reporting on Moore’s donor-registration advocacy